6533b833fe1ef96bd129b87a
RESEARCH PRODUCT
IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments.
Erik EllwardtFrauke ZippDirk LuchtmanCatherine Larochellesubject
Central Nervous SystemPathologymedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyAutoimmunityNeurological disorderGeneral Biochemistry Genetics and Molecular BiologyUnmet needsPathogenesisMicemedicineImmunology and AllergyAnimalsHumansEffectorbusiness.industryMultiple sclerosisInterleukin-17Cell DifferentiationImmunotherapyInterferon-betamedicine.diseaseClinical trialImmunologyTh17 CellsInterleukin 17ImmunotherapyInflammation Mediatorsbusinessdescription
Multiple sclerosis (MS), an autoimmune neurological disorder, is driven by self-reactive T helper (Th) cells. Research on the role of Th17 lymphocytes in MS pathogenesis has made significant progress in identifying various immunological as well as environmental factors that induce the differentiation and expansion of these cells, different subsets of Th17 cells with varying degrees of pathogenicity, and the role of the secreted effector cytokines. While approved therapies for MS offer significant benefit to patients, there remain unmet needs. Ongoing clinical trials aim to translate the advanced knowledge of Th17 cytokines to improved therapies. This review discusses the current status and future developments of research into the role of Th17 and related cytokines in MS pathogenesis and therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-08-01 | Cytokinegrowth factor reviews |